91 related articles for article (PubMed ID: 22796461)
21. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Curtin JP; Blessing JA; Soper JT; DeGeest K
Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
25. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Aghajanian C; Sill MW; Secord AA; Powell MA; Steinhoff M
Gynecol Oncol; 2012 Sep; 126(3):424-7. PubMed ID: 22634397
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide in patients with malignant pleural mesothelioma.
Baas P; Boogerd W; Dalesio O; Haringhuizen A; Custers F; van Zandwijk N
Lung Cancer; 2005 May; 48(2):291-6. PubMed ID: 15829331
[TBL] [Abstract][Full Text] [Related]
28. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Toyoshima M; Akahira J; Matsunaga G; Niikura H; Ito K; Yaegashi N; Tase T
Gynecol Oncol; 2004 Sep; 94(3):774-8. PubMed ID: 15350372
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna C; Baccarani M; Cavo M
Ann Hematol; 2012 Mar; 91(3):419-26. PubMed ID: 21901342
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
36. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
Corso A; Zappasodi P; Barbarano L; Petrucci MT; Palumbo A; Caravita T; Mangiacavalli S; Cafro AM; Varettoni M; Gay F; Morra E; Lazzarino M
Leuk Res; 2009 Sep; 33(9):e145-9. PubMed ID: 19375164
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
